Related Experiment Video
Updated: Apr 26, 2026
05:45
Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
Published on: January 19, 2024
3.2K
Treating glioblastoma in the elderly
Jaime Gállego Pérez-Larraya1, Jean-Yves Delattre
1Department of Neurology, Neuro-Oncology Unit, Clínica Universidad de Navarra, Universidad de Navarra, Av. Pío XII 36, 31008 Pamplona, Spain.
CNS Oncology
|July 25, 2014
Summary
Glioblastoma (GBM) is increasing in older adults. Active treatment, including surgery, radiation, and chemotherapy, improves survival and quality of life in elderly GBM patients.
Area of Science:
- Neuro-oncology
- Geriatric oncology
Background:
- Glioblastoma (GBM) incidence is rising in elderly populations, representing up to 50% of adult cases.
- This demographic shift necessitates dedicated clinical research for older, often fragile, GBM patients.
Purpose of the Study:
- To evaluate the impact of active treatment strategies on survival and quality of life in elderly patients with glioblastoma.
- To emphasize that age alone should not be a barrier to etiological treatments for GBM in older adults.
Main Methods:
- Review of prospective studies investigating surgical resection, radiotherapy, and chemotherapy with temozolomide in elderly GBM patients.
- Analysis of combined radiochemotherapy approaches in this population.
Main Results:
- Prospective studies indicate that active care significantly improves survival in older GBM patients.
- Active treatment does not negatively impact quality of life or cognitive function in this cohort.
Conclusions:
- Elderly patients with glioblastoma benefit from aggressive treatment, including surgery, radiotherapy, and chemotherapy.
- Treatment decisions for older GBM patients must consider performance status, cognitive function, tumor resectability, and comorbidities to optimize outcomes.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
392
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
392
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
365
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
365
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
849
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
849
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K